Biotherapic produced from serum of refractory to Trypanosoma cruzi animal increases survival in mice infected with the protozoan.
Trypanosoma cruzi infection affects approximately eight million people from the Southern United States to Southern Argentina1, with 1.5 million of them in Brazil. The lack of an effective medication for the causative treatment of this infection arouses the interest of many researchers. Considering the data obtained by our team regarding the effects of biotherapic in murine infection with T. cruzi2-7, the relationship of the effects of biotherapic with the biological material used and the species from which this material is collected, the resistance or susceptibility of this species against the pathology to be treated2-7, and the refractoriness of birds8 to T. cruzi, in this study we evaluated the effects of ultradiluted serum of Gallus gallus domesticus on the treatment of mice infected with Trypanosoma cruzi. Methodology: In a blind, controlled and randomized assay, 21 male Swiss mice, eight weeks-old, were allocated into three groups: CI: infected animals without treatment(n=7); Alcohol13cH: infected and treated with alcohol 13cH animals(n=7); Serum13cH: infected and treated with serum of Gallus gallus domesticus 13cH animals(n = 7). The Infected animals were inoculated with 1400 blood trypomastigotes of T. cruzi-Y strain. Medications were prepared from uninfected serum of Gallus gallus domesticus according Brazilian Pharmacopoeia Homeopathy9 and administered two days before infection and on days 2, 5 and 8 after infection. The medication was diluted in the drinking water at concentration of 1% and offered ad libitum overnight. The groups were evaluated regarding survival period up to 161 days (endpoint). The project was submitted to the Ethics Committee CEUA Nº 2401220716 . Results: Data are presented in Figure 1. The animals that received treatment with Gallus gallus domesticus serum 13cH(Serum 13cH) had higher survival rate(p